3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Head & Neck
3
Breast
3
Other hematologic neoplasm
1
Conditions
Pathologic Complete Response
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
678
Cytarabine
576
fludarabine
410
fludarabine phosphate
387
venetoclax
310
Methotrexate
297
Rituximab
283
Azacitidine
264
Busulfan
248
Whole-Body Irradiation
220
Etoposide
215
Filgrastim
214
Peripheral Blood Stem Cell Transplantation
211
Mycophenolic Acid
206
Tacrolimus
196
Dexamethasone
191
Granulocyte Colony-Stimulating Factor
182
Vincristine
173
Melphalan
173
Decitabine
163
Cyclosporine
146
Daunorubicin
139
Antilymphocyte Serum
137
Idarubicin
134
Imatinib Mesylate
127
Lenalidomide
116
Doxorubicin
109
Radiotherapy
108
Stem Cell Transplantation
107
Clofarabine
106
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Sulindac
×
Other hematologic neoplasm
×
Clear all
NCT01843179
2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2
Withdrawn